Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
6.01
+0.07 (1.18%)
At close: Mar 6, 2026, 4:00 PM EST
6.00
-0.01 (-0.17%)
After-hours: Mar 6, 2026, 4:41 PM EST
Minerva Neurosciences Employees
Minerva Neurosciences had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,753,445
Market Cap
260.08M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Coherus Oncology | 158 |
| Abeona Therapeutics | 136 |
| Prelude Therapeutics | 131 |
| OmniAb | 114 |
| Enlivex | 71 |
| Cybin | 50 |
| Surrozen | 41 |
NERV News
- 4 days ago - Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript - Seeking Alpha
- 5 weeks ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 3 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire
- 7 months ago - Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewsWire
- 10 months ago - Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire